PD08-08 TIME TO SECOND BIOCHEMICAL RECURRENCE AS A PROGNOSTIC INDICATOR IN POST-PROSTATECTOMY PATIENTS WHO UNDERGO SALVAGE RADIATION THERAPY: AN RTOG 9601 BASED POST-HOC ANALYSIS

You have accessJournal of UrologyProstate Cancer: Localized: Radiation Therapy (PD08)1 Sep 2021PD08-08 TIME TO SECOND BIOCHEMICAL RECURRENCE AS A PROGNOSTIC INDICATOR IN POST-PROSTATECTOMY PATIENTS WHO UNDERGO SALVAGE RADIATION THERAPY: AN RTOG 9601 BASED POST-HOC ANALYSIS Emily Chan, Akshay Sood, Jacob Keeley, Nicholas Corsi, Marcus Jamil, Deepansh Dalela, Mani Menon, Craig Rogers, and Firas Abdollah ChanEmily Chan More articles by this author , SoodAkshay Sood KeeleyJacob Keeley CorsiNicholas Corsi JamilMarcus Jamil DalelaDeepansh Dalela MenonMani Menon RogersCraig Rogers AbdollahFiras View All Author Informationhttps://doi.org/10.1097/JU.0000000000001976.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The prognostic significance a ‘second’ biochemical recurrence (sBCR) after salvage radiation therapy (sRT) with/without hormonal following primary radical prostatectomy in men with prostate cancer has not been examined. We hypothesized that shorter time sBCR will be associated worse control outcomes. METHODS: study included 760 patients tumor stage pT2/T3, pN0, who had either persistent PSA post-radical or developed subsequent levels between 0.2 4.0 ng/mL. received sRT (with without 2-years Bicalutamide) from years 1998 2015. For our study, we focused on 421 sRT. was defined as values above ng/mL over the first nadir. Patients were divided into two categories: early (n=210) late (n=211) using median (3.5 years). experienced therapy. Time-varying Fine-Gray analysis used examine impact vs later prostate-cancer specific mortality (CSM), accounting for covariates. RESULTS: majority age 60 older (75.8%), pT3 disease (74.8%), Gleason score ³7 (75.2%). Overall, 13.8% initially surgery. At 10-year, CSM rate 31.2% group 20.3% (p=0.03, Figure 1). In competing-risk analysis, an independent predictor CSM, where 1.7-fold higher risk (p=0.026) than their counterparts sBCR. CONCLUSIONS: Time concomitant is significant initial prostatectomy. This information can guide treatments, counsel patients. Source Funding: N/A © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e116-e117 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...